Tumor Differentiation and the Role of Nuclear Medicine Scintigraphy and Therapy

Tumor differentiation is a biologic process that significantly influences molecular imaging patterns and therapeutic response. This review examines how tumor differentiation shapes theranostic strategy across thyroid, neuroendocrine, and prostate cancers, with particular attention to the inverse association between tumor differentiation and glucose metabolism. In thyroid and neuroendocrine tumors, well-differentiated disease retains tissue-specific transporters and receptors, such as the sodium-iodide symporter and somatostatin receptors, enabling function-based imaging and targeted therapy. Well-differentiated neuroendocrine tumors upregulate somatostatin receptor expression. Conversely, poorly differentiated tumors in these categories lose these specialized features and exhibit enhanced glycolytic metabolism, resulting in increased [<sup>18</sup>F]FDG uptake. In prostate cancer, the differentiation-metabolism relationship is more complex. Prostate-specific membrane antigen (PSMA) is a membrane protein expressed on the apical surface of endothelial cells in prostate and nonprostate tissue. It is weakly expressed in normal prostate tissue but upregulated in prostate cancer and several solid malignancies. Within prostate adenocarcinoma, PSMA expression generally increases with higher Gleason score and tumor aggressiveness, making dedifferentiating tumors and metastatic disease highly PSMA-avid on imaging and suitable for PSMA-targeted therapy. However, in treatment-emergent neuroendocrine prostate cancer, PSMA expression may be lost despite intense [<sup>18</sup>F]FDG uptake, reflecting lineage plasticity rather than classical dedifferentiation. This tumor-specific differentiation-driven model has significant implications for patient management, treatment planning, and prognosis. Understanding these tumor-specific differentiation patterns allows clinicians to optimize diagnostic imaging and therapeutic strategies in precision oncology and personalized medicine.

Authors

Institutions

Publication Details

Journal
Journal of Nuclear Medicine Technology
Published
2025-12-01
DOI
https://doi.org/10.2967/jnmt.125.271082
Citations
1
Primary Topic
Prostate Cancer Treatment and Research
Type
article
Field-Weighted Citation Impact
1.52
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Tumor Differentiation and the Role of Nuclear Medicine Scintigraphy and Therapy

Julie Dawn Bolin
1 citations
Journal of Nuclear Medicine Technology
Prostate Cancer Treatment and Research
1.52
article

Tumor Differentiation and the Role of Nuclear Medicine Scintigraphy and Therapy

Julie Dawn Bolin
article en
1 citations

Abstract

Tumor differentiation is a biologic process that significantly influences molecular imaging patterns and therapeutic response. This review examines how tumor differentiation shapes theranostic strategy across thyroid, neuroendocrine, and prostate cancers, with particular attention to the inverse association between tumor differentiation and glucose metabolism. In thyroid and neuroendocrine tumors, well-differentiated disease retains tissue-specific transporters and receptors, such as the sodium-iodide symporter and somatostatin receptors, enabling function-based imaging and targeted therapy. Well-differentiated neuroendocrine tumors upregulate somatostatin receptor expression. Conversely, poorly differentiated tumors in these categories lose these specialized features and exhibit enhanced glycolytic metabolism, resulting in increased [<sup>18</sup>F]FDG uptake. In prostate cancer, the differentiation-metabolism relationship is more complex. Prostate-specific membrane antigen (PSMA) is a membrane protein expressed on the apical surface of endothelial cells in prostate and nonprostate tissue. It is weakly expressed in normal prostate tissue but upregulated in prostate cancer and several solid malignancies. Within prostate adenocarcinoma, PSMA expression generally increases with higher Gleason score and tumor aggressiveness, making dedifferentiating tumors and metastatic disease highly PSMA-avid on imaging and suitable for PSMA-targeted therapy. However, in treatment-emergent neuroendocrine prostate cancer, PSMA expression may be lost despite intense [<sup>18</sup>F]FDG uptake, reflecting lineage plasticity rather than classical dedifferentiation. This tumor-specific differentiation-driven model has significant implications for patient management, treatment planning, and prognosis. Understanding these tumor-specific differentiation patterns allows clinicians to optimize diagnostic imaging and therapeutic strategies in precision oncology and personalized medicine.

Journal of Nuclear Medicine TechnologyVol. 53(Supplement 1)
WestCon Medical (United States) (US), Banner - University Medical Center Tucson (US), GateWay Community College (US)
Openalex Percentile: Top 12%
Prostate Cancer Treatment and Research
1.52
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.